The Phase 3 DexEnceph trial found that adjunct dexamethasone is safe in adults with HSV encephalitis but does not significantly improve verbal memory scores at 26 weeks compared to aciclovir monotherapy, suggesting a need for earlier or more targeted immunomodulation.